Galmed Pharma (GLMD) Tops Q3 EPS by 3c

Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $330 thousand.

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Carvana's share gains and production growth remain on track, Wells Fargo says